Hepatitis C increases risk of non-Hodgkin lymphoma

May 08, 2007

Hepatitis C infection is associated with an increased risk of non-Hodgkin lymphoma (malignancy involving lymphatic tissue) of 20 percent to 30 percent, and a three-fold increase in the risk of another type of lymphoma, according to a study in the May 9 issue of JAMA.

The prevalence of hepatitis C virus (HCV) is estimated at 1.6 percent of the U.S. population. It is more common among U.S. military veterans who use the Veterans Affairs (VA) medical system, in which approximately five percent of veterans are infected with HCV. HCV infection causes liver cancer and cirrhosis, and may also increase the risk of other tumors. Previous studies have been too small to adequately assess these risks, according to background information in the article.

Thomas P. Giordano, M.D., M.P.H., of Baylor College of Medicine and the Michael E. DeBakey Veterans Affairs Medical Center, Houston, and colleagues conducted a retrospective cohort study to test the hypothesis that HCV infection is associated with increased risk for malignancies of the blood and blood-forming tissues, related disorders, and thyroid cancer. The study involved patients from U.S. Veterans Affairs health care facilities from 1997-2004 and included 146,394 individuals infected with HCV, and 572,293 not infected with HCV. The research examined the risks of hematopoietic malignancies (relating to the formation of blood cellular components), related lymphoproliferative precursor diseases (referring to the proliferation of the bone marrow cells that give rise to lymphoid cells), and thyroid cancer.

There were 1,359 cases of non-Hodgkin lymphoma, 165 cases of Waldenström macroglobulinemia (a low grade lymphoma), 551 cases of cryoglobulinemia and 320 cases of thyroid cancer.

"We found a small but significant 20 percent to 30 percent increase in the risk of NHL [non-Hodgkin lymphoma], including all subtypes, and an almost three-fold increased risk of the low-grade lymphoma subtype Waldenström macroglobulinemia in persons with HCV infection," the authors report. Low-grade lymphoma tends to grow and spread slowly.

HCV infection was also associated with an increased risk of nonmalignant plasma cell disorders.

"We demonstrated that infection precedes development of these outcomes, and that the risk in individuals infected with HCV is consistently increased, with over five years of follow-up," the authors continue.

The study found no significantly increased risk for other hematological malignancies. The risk for thyroid cancer was not increased.

"Although the clinical significance of these findings is unknown, it is possible that screening of individuals infected with HCV could identify early stage lymphoproliferative conditions suitable for early intervention strategies, including chemoprevention trials on premalignant disease. Future epidemiological and pathophysiological studies are needed to further explore the relationship between HCV and NHL," the authors conclude.
(JAMA. 2007;297:2010-2017. Available pre-embargo to the media at www.jamamedia.org.)

Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

For more information, contact the JAMA/Archives Media Relations Department at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org .

The JAMA Network Journals

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.